Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Recurrence 2Leukemia, Myeloid, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Burkitt Lymphoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Dexamethasone 29Cyclophosphamide 21Rituximab 17Cytarabine 16Bortezomib 13Gemcitabine 12fludarabine 11Methotrexate 11Lenalidomide 10Filgrastim 10Vincristine 9Etoposide 9pomalidomide 8pembrolizumab 8Paclitaxel 8Azacitidine 8venetoclax 7carfilzomib 7Doxorubicin 7Docetaxel 7Cyclosporine 7Calcium Dobesilate 7Antilymphocyte Serum 7fludarabine phosphate 6Topotecan 6Temozolomide 6Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6Mitoxantrone 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Recurrence × tagraxofusp × Clear all
NCT04342962 2025-01-30

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Terminated
25 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02661022 2024-04-17

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Stemline Therapeutics, Inc.

Phase 1/2 Terminated
9 enrolled 13 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡